Sight Sciences (NASDAQ:SGHT) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Sight Sciences (NASDAQ:SGHT) posted its quarterly earnings data on Wednesday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01), Zacks reports. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. Sight Sciences updated its FY 2025 guidance to EPS.

Sight Sciences Stock Performance

Shares of SGHT traded down $0.05 during mid-day trading on Wednesday, hitting $2.42. 306,586 shares of the company traded hands, compared to its average volume of 250,791. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The stock has a 50-day moving average price of $2.97 and a two-hundred day moving average price of $4.46. Sight Sciences has a 1 year low of $2.29 and a 1 year high of $8.45. The stock has a market cap of $122.83 million, a price-to-earnings ratio of -2.37 and a beta of 2.52.

Wall Street Analysts Forecast Growth

SGHT has been the topic of several recent research reports. Lake Street Capital reduced their target price on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, January 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Tuesday, January 14th. Stifel Nicolaus reduced their target price on shares of Sight Sciences from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, February 6th. UBS Group reduced their target price on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating on the stock in a report on Monday, January 27th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $5.50 target price (down previously from $6.00) on shares of Sight Sciences in a report on Friday, November 8th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Sight Sciences has a consensus rating of “Hold” and an average target price of $4.42.

Insider Activity

In related news, CEO Paul Badawi sold 24,819 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $2.92, for a total transaction of $72,471.48. Following the completion of the sale, the chief executive officer now directly owns 5,676,331 shares in the company, valued at approximately $16,574,886.52. The trade was a 0.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 63,014 shares of company stock valued at $197,295 over the last three months. Insiders own 28.90% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.